Carlsmed, Inc. expected to post a loss of 41 cents a share - Earnings Preview
Carlsmed, Inc. expected to post a loss of 41 cents a share - Earnings Preview
Carlsmed, Inc. CARL.OQ CARL.O is expected to report resultson August 5 for the period ending June 30 2026
The Carlsbad California-based company is expected to report revenue of $17.948 million, according to the mean estimate from 5 analysts, based on LSEG data.
LSEG's mean analyst estimate for Carlsmed, Inc. is for a loss of 41 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Carlsmed, Inc. is $18.00, about 39.2% above its last closing price of $12.93
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2026 | -0.39 | -0.39 | -0.32 | Beat | 18.4 |
Dec. 31 2026 | -0.45 | -0.43 | -0.32 | Beat | 24.9 |
Sep. 30 2025 | -0.49 | -0.45 | -0.40 | Beat | 11.9 |
| |||||
|
This summary was machine generated August 4 at 00:37 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Recent news on Carlsmed
See all newsBrief: Carlsmed May Offer Up To $250 Million In Securities
Carlsmed, Inc. reports results for the quarter ended June 30 - Earnings Summary
Carlsmed Q2 revenue rises 57%, raises 2026 revenue forecast
Carlsmed, Inc. expected to post a loss of 41 cents a share - Earnings Preview
Brief: Carlsmed Announces CMS Finalizes Favorable Reimbursement For aprevo Lumbar Procedures In FY2027